Authors

Latest:

Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need

Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2024.

Yadav Sapkota, PhD

Latest:

Impact of Genetic Variant on Stroke Risk in Childhood Cancer Survivors Treated With Cranial Radiation Therapy

Yadav Sapkota, PhD, clinical research scientist at St. Jude Children’s Research Hospital, discusses the relationship between a genetic variant and the risk of stroke in childhood cancer survivors treated with cranial radiation therapy.

Yale

Latest:

Roy S. Herbst, MD, PhD, Honored by IASLC

Roy S. Herbst, MD, PhD, was honored by the International Association for the Study of Lung Cancer in recognition for his years of dedication and invaluable service to the organization and the lung cancer community.

Yana Pikman, MD

Latest:

Dr. Pikman on Implications of a Matched Targeted Therapy Approach in Pediatric Leukemia

Yana Pikman, MD, a physician in the Cancer and Blood Disorders Center at Dana-Farber Cancer Institute and instructor of pediatrics at Harvard Medical School, discusses the implications of a matched targeted therapy approach in pediatric leukemia.

Yara Abdou, MD

Latest:

Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.

Yardena Samuels, PhD

Latest:

Yardena Samuels on RASA2 as Prognostic Biomarker in Melanoma

Yardena Samuels, PhD, Tenured Associate Professor, Department of Moleular Cell Biology, the Weizmann Institute of Science, Israel, discuses her lab’s discovery of a potential prognostic biomarker in cutaneous sporadic melanoma.

Yasuhiro Funahashi, MD

Latest:

Dr. Funahashi on Enhanced Activity With Lenvatinib/Everolimus Combo in RCC

Yasuhiro Funahashi, MD, senior director, Eisai, discusses a study exploring the enhanced antitumor activity with the combination of lenvatinib (Lenvima) and everolimus (Afinitor) in patients with renal cell carcinoma (RCC).

Yasuhiro Oki, MD

Latest:

Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review

The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.

Yasushi Goto, MD, PhD

Latest:

Dr Goto on Datopotamab Deruxtecan Plus Pembrolizumab and Chemotherapy in Advanced NSCLC

Yasushi Goto, MD, discusses primary efficacy findings from the phase 1 TROPION-Lung02 trial of datopotamab deruxtecan plus pembrolizumab with or without platinum-based chemotherapy in patients with advanced non–small cell lung cancer.

Yee Chung Cheng, MD

Latest:

Dr. Cheng on the Role of T-DM1 in HER2+ Breast Cancer

Yee Chung Cheng, MD, associate professor of medicine, Medical College of Wisconsin, discusses the role of T-DM1 in patients with HER2-positive breast cancer.

Yelena Novik, MD

Latest:

Dr Novik on Emergent Treatment Options in ER+ Breast Cancer

Yelena Novik, MD, discusses advancements and emerging trends that have been seen in the treatment of patients with advanced estrogen-receptor–positive breast cancer, citing clinical trials that have helped push the treatment armamentarium forward.

Yelena Y. Janjigian, MD

Latest:

Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma

Yelena Y. Janjigian, MD, discusses the significance of the FDA approval of zolbetuximab plus chemotherapy for HER2–, CLDN18.2+ gastric/GEJ adenocarcinoma.

Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center

Latest:

Global Updates in Advanced Gastric Cancer from ESMO 2020

Yeon Hee Park, MD

Latest:

Dr. Park on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer

Yeon Hee Park, MD, discusses the utility and benefit of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer, specifically in patients with central nervous system metastases.

Yi-Bin A. Chen, MD, Massachusetts General Hospital

Latest:

Dr. Chen on Risk Factors for Developing cGVHD

Yi-Bin Chen, MD, discusses risk factors for developing chronic graft-vs-host disease in patients who receive an allogeneic transplant.

Yin Zhang, PhD

Latest:

Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis

Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.

Yixing Jiang, BM, PhD

Latest:

Dr. Jiang on the Future of Immunotherapy in Microsatellite Stable Colorectal Cancer

Yixing Jiang, BM, PhD, associate professor of medicine, director, Gastrointestinal Medical Oncology Marlene Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, discusses the future of immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Yixuan Gong, PhD

Latest:

Whole-Blood, 6-Gene Prognostic Signature May Help Personalize Prostate Cancer Treatment

Drs William Oh and Yixuan Gong discuss their research involving a whole-blood, 6-gene prognostic signature that has the potential to help personalize prostate cancer treatment.

Yogen Saunthararajah, MD

Latest:

Novel AML Strategies Aim to Restore Regulatory Gene Functions

Acute promyelocytic leukemia, a rare genetic subtype of de novo acute myeloid leukemia is treated not with conventional cytotoxic chemotherapy but with just 2 drugs: all-trans retinoic acid and arsenic trioxide. Given this, an enduring question has been whether noncytotoxic differentiation-restoring therapy can be extended to the most common genetic subtypes of AML.

Yogenthiran Saunthararajah, MD

Latest:

Dr. Saunthararajah on Mechanisms of Resistance to 5-Azacytidine /Decitabine in MDS-AML

Yogenthiran Saunthararajah, MD, Department of Hematologic Oncology and Blood Disorders at Cleveland Clinic, professor of Medicine, co-leader, Developmental Therapeutics Program of the Case Comprehensive Cancer Center, discusses mechanisms of resistance to 5-azacytidine and decitabine in patients with myelodysplastic syndromes-acute myeloid leukemia.